However, recent publications linking Hsp90 function with cancer immune modulation and showing how Hsp90 inhibition may enhance cancer immunotherapy in preclinical models have revived the interest in the combination of Hsp90i and ICB in the clinic (62, 63). The gene discussed is HSP90AB1; the disease is cancer.